Gene · 246100
Papers4,157
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
141 to 160 of 4,157
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Liposome-based in situ antigen-modification strategy for "universal" T-cell-receptor engineered T cell in cancer immunotherapy. | MedComm (2020) | 2024 | 38974711 | PubTator, text mining | PubMed |
| Automated immunoassay of serum NY-ESO-1 and XAGE1 antibodies for predicting clinical benefit with immune checkpoint inhibitor (ICI) in advanced non-small cell lung cancer. | Cancer Treat Res Commun | 2024 | 38964205 | PubTator, text mining | PubMed |
| Restoration of ARID1A Protein in ARID1A-deficient Clear Cell Carcinoma of the Ovary Attenuates Reactivity to Cytotoxic T Lymphocytes. | Cancer Genomics Proteomics | 2024 | 38944423 | PubTator, text mining | PubMed |
| Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma. | Cancer Res Commun | 2024 | 38934093 | PubTator, text mining | PubMed |
| Expression of the tumor antigens NY-ESO-1, tyrosinase, MAGE-A3, and TPTE in pediatric and adult melanoma: a retrospective case control study. | Virchows Arch | 2024 | 38890171 | PubTator, text mining | PubMed |
| Single-cell sequencing unveils extensive intratumoral heterogeneity of cancer/testis antigen expression in melanoma and lung cancer. | J Immunother Cancer | 2024 | 38886115 | PubTator, text mining | PubMed |
| PD-1-CD28-enhanced receptor and CD19 CAR-modified tumor-infiltrating T lymphocytes produce potential anti-tumor ability in solid tumors. | Biomed Pharmacother | 2024 | 38788547 | PubTator, text mining | PubMed |
| Germline homozygosity and allelic imbalance of HLA-I are common in esophagogastric adenocarcinoma and impair the repertoire of immunogenic peptides. | J Immunother Cancer | 2024 | 38631707 | PubTator, text mining | PubMed |
| STING agonist diABZI enhances the cytotoxicity of T cell towards cancer cells. | Cell Death Dis | 2024 | 38615022 | PubTator, text mining | PubMed |
| The bright side of chemistry: Exploring synthetic peptide-based anticancer vaccines. | J Pept Sci | 2024 | 38571326 | PubTator, text mining | PubMed |
| Cancer biomarkers: Emerging trends and clinical implications for personalized treatment. | Cell | 2024 | 38552610 | PubTator, text mining | PubMed |
| TIM-3, LAG-3, or 2B4 gene disruptions increase the anti-tumor response of engineered T cells. | Front Immunol | 2024 | 38510235 | PubTator, text mining | PubMed |
| Serum NY-ESO-1 and p53 antibodies as useful tumor markers in gastric cancer. | Ann Gastroenterol Surg | 2024 | 38455491 | PubTator, text mining | PubMed |
| Silver nanoparticles enhanced enzyme-linked immunosorbent assay (ELISA) detection of cancer testis antigens (CTAs). | Eur Rev Med Pharmacol Sci | 2024 | 38436175 | PubTator, text mining | PubMed |
| Designing, cloning and simulation studies of cancer/testis antigens based multi-epitope vaccine candidates against cutaneous melanoma: An immunoinformatics approach. | Biochem Biophys Rep | 2024 | 38371523 | PubTator, text mining | PubMed |
| NY-ESO-1-specific T cell receptor-engineered T cells and Tranilast, a TRPV2 antagonist bivalent treatment enhances the killing of esophageal cancer: a dual-targeted cancer therapeutic route. | Cancer Cell Int | 2024 | 38336680 | PubTator, text mining | PubMed |
| Serum NY-ESO-1 antibody as a predictive biomarker for postoperative recurrence of gastric cancer: a multicenter prospective observational study. | Br J Cancer | 2024 | 38326601 | PubTator, text mining | PubMed |
| New trends in diagnosis and management of gallbladder carcinoma. | World J Gastrointest Oncol | 2024 | 38292841 | PubTator, text mining | PubMed |
| Recent progress in mRNA cancer vaccines. | Hum Vaccin Immunother | 2024 | 38282471 | PubTator, text mining | PubMed |
| Role of Immunotherapy in Sarcomas. | Int J Mol Sci | 2024 | 38279265 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/246100/papers?page=8